ReadCoor

Cambridge, United States Founded: 2016 • Age: 10 yrs Acquired By 10X Genomics
Fluorescent in situ RNA sequencing technology

About ReadCoor

ReadCoor is a Healthcare company based in Cambridge (United States) founded in 2016, and was acquired by 10X Genomics in October 2020. Fluorescent in situ RNA sequencing technology. It operates in the Healthcare and Technology sectors. ReadCoor has raised $55.61 million across 5 funding rounds from investors including 10X Genomics, The Chan Zuckerberg Initiative and Gates Foundation. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Instrument Systems. Its legal entity is READCOOR, INC. Its competitors include PacBio, Alnylam and Omniome; 3 of its 3 listed competitors have raised funding.

Company details

ReadCoor was founded in 2016 in Cambridge, United States, within the biotechnology sector. A next-generation sequencing platform is being developed and commercialized, allowing high-throughput RNA sequencing alongside preservation of sample morphology and integration of spatial imaging data. FISSEQ technology supports applications in drug development, pathogen identification, disease diagnostics, regenerative medicine, immuno-oncology, gene therapy, and brain diseases, originating from Harvards Dr. Church lab.

Key Metrics
  • Total Equity Funding
    $55.61M (USD)

    in 5 rounds

  • Latest Funding Round
    $30M (USD), Series B

    Jan 2020

  • Investors
  • Acquired by
    10X Genomics

    (Oct 2020)

Apps and channels of ReadCoor

its YouTube channel 10x Genomics has 6.98K subscribers and 30 videos.

10x Genomics
YouTube 6.98K subscribers 30 videos Science & Technology
Open channel

Videos from ReadCoor

The most watched videos on ReadCoor's YouTube channel, 10x Genomics (6.98K subscribers). Click a video to play it here.

Explore Visium HD Data in less than 13 Minutes – Loupe Browser Tutorial
3K views
Life at 10x Genomics
1.5K views
【空間的解析】東京大学の鈴木穣先生、鈴木絢子先生に聞くXeniumが可能にする空間的解析の世界
1K views
Experience the power of spatial transcriptomics from 10x Genomics Part 2
688 views

More on 10x Genomics.

Funding Insights of ReadCoor

ReadCoor has successfully raised a total of $55.61M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $30 million completed in January 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $55.61M
  • Total Rounds 5
  • Last Round Series B — $30M
  • First Round $23M

    (Sep 2016)

  • Investors Count 8

All 5 funding rounds of ReadCoor with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jan 2020$30MSeries B–Pavilion Capital Partners
Jul 2019$2.61MSeries A––
–
Jan 2018Grant––
Dec 2016Grant––
Sep 2016$23MSeries A–Decheng Capital
Valuation history

9 investors in total: 8 institutional and 1 angel.

Investors in ReadCoor

ReadCoor has secured backing from 9 investors, including venture fund, angel, and institutional investors. Prominent investors backing the company include 10X Genomics, The Chan Zuckerberg Initiative and Gates Foundation.

All
Venture Fund
Institutional
Angel
InvestorDescriptionFounded YearDomainLocation
Growth-stage companies are invested in by this venture capital fund.
pavilioncapital.comNew York, United States
Venture capital firm focused on life science and technology sectors
decheng.comShanghai, China
Venture capital and private equity firm
vivocapital.comPalo Alto, United States
Foundation engaged in the areas of science, education, and justice
2015chanzuckerberg.comRedwood City, United States
Truck brands are manufactured by DAF in Eindhoven, Netherlands.
1928daf.comEindhoven, Netherlands
Charitable foundation investments on poverty reduction and healthcare
2000gatesfoundation.orgSeattle, United States
lillyasiaventures.com

Hansjorg Wyss

unknown_01930b6f0a6d4e269
Instrument systems for genomic research and sequencing libraries are developed.
201210xgenomics.comPleasanton, United States
Premium access

Investor details for ReadCoor

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Timeline of ReadCoor

4 dated milestones of ReadCoor across 4 years, from founding to its latest funding, stage changes and deals.

  1. Founded ReadCoor is founded.
  2. Funding First funding round of $23.0M.
  3. Funding Latest funding round, Series B, of $30.0M.
  4. Exit Acquired by 10X Genomics.

Competitors of ReadCoor

ReadCoor has 3 listed competitors in our database, 3 of them funded. They include PacBio, Alnylam and Omniome.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
pacb.com2004Menlo Park, United States$395M649
Instrument systems and software for single-molecule real-time sequencing are developed.
alnylam.com2002Cambridge, United States$17M2,100
RNA interference-based therapeutics are developed for multiple disorders.
omniome.com2013San Diego, United States$160.23M164
Genome sequencing platform is provided for clinical diagnostics.
Premium access

Detailed competitors of ReadCoor

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Genomics & Gene Therapy Platforms

3 companies that operate in the same segment as ReadCoor (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Digital sequencing technology for cancer detection is developed.
2012Redwood City, California, United StatesUSD 557.5 MUSD 982.02 M4,867
Circulating tumor DNA is screened for early cancer detection.
2016Menlo Park, California, United StatesUSD 2 BUSD 147.17 M1,141
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Readcoor

Premium access

Complete news archive for ReadCoor

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about ReadCoor

ReadCoor was founded in 2016.

ReadCoor is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.

ReadCoor is a funded company, having raised a total of $55.61M across 5 funding rounds to date. The company's 1st funding round was a Series A of $23M, raised on Sep 2016.

ReadCoor was founded in 2016 in Cambridge, United States, within the biotechnology sector. A next-generation sequencing platform is being developed and commercialized, allowing high-throughput RNA sequencing alongside preservation of sample morphology and integration of spatial imaging data. FISSEQ technology supports applications in drug development, pathogen identification, disease diagnostics, regenerative medicine, immuno-oncology, gene therapy, and brain diseases, originating from Harvards Dr. Church lab.

ReadCoor's top competitors include Alnylam, PacBio and Omniome.

ReadCoor operates through Readcoor, Inc..

Yes. ReadCoor was acquired by 10X Genomics in October 2020.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available